Compare APO & CI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APO | CI |
|---|---|---|
| Founded | 1990 | 1792 |
| Country | United States | United States |
| Employees | 6104 | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.3B | 76.8B |
| IPO Year | N/A | 2018 |
| Metric | APO | CI |
|---|---|---|
| Price | $108.45 | $271.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $155.92 | ★ $345.79 |
| AVG Volume (30 Days) | ★ 6.0M | 1.6M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | 1.83% | ★ 2.22% |
| EPS Growth | N/A | ★ 83.00 |
| EPS | N/A | ★ 22.18 |
| Revenue | N/A | ★ $274,900,000,000.00 |
| Revenue This Year | N/A | $5.75 |
| Revenue Next Year | $8.67 | $5.90 |
| P/E Ratio | $22.63 | ★ $12.68 |
| Revenue Growth | N/A | ★ 11.24 |
| 52 Week Low | $99.56 | $239.51 |
| 52 Week High | $157.28 | $350.00 |
| Indicator | APO | CI |
|---|---|---|
| Relative Strength Index (RSI) | 33.94 | 39.19 |
| Support Level | N/A | $267.61 |
| Resistance Level | $138.90 | $279.16 |
| Average True Range (ATR) | 5.19 | 6.58 |
| MACD | -0.35 | -1.58 |
| Stochastic Oscillator | 32.73 | 13.34 |
Apollo is one of the world's largest alternative asset managers, with $908.4 billion in total assets under management, or AUM, including $685.0 billion in fee-earning assets, at the end of September 2025. The company has two core operating segments: asset management and retirement services. Apollo operates with scale in each of its major product lines-private equity (with $125.6 billion in total AUM and $71.7 billion in fee-earning AUM), real estate/real assets ($59.6 billion/$27.1 billion), and private credit ($723.2 billion/$586.2 billion). Apollo has a distribution profile that is likely not too far off from the industry averages-with 84% of its assets held by institutional investors and 16% by high-net-worth clients.
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.